GlobeNewswire·Feb 17, 2026, 8:00 AM ET

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics will host a conference call & webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET to present 12-week results from the 20 mg dose cohort of the Phase 1b PIONEER trial.
The trial evaluates pociredir for the treatment of sickle cell disease & includes management members alongside Dr. Martin Steinberg from Boston University.
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) designed to increase fetal hemoglobin (HbF) expression.
Prior data from the PIONEER trial showed dose-dependent increases in HbF, pan-cellular HbF induction, & improvements in hemolysis & anemia markers.
The drug has been generally well-tolerated across 12 mg & 20 mg dose cohorts with up to three months of exposure & no treatment-related serious adverse events reported.
The FDA has granted Fast Track & Orphan Drug Designations to pociredir for sickle cell disease treatment.
Sickle cell disease is a genetic disorder caused by an HBB gene mutation leading to inefficient oxygen transport, sickle-shaped cells, & serious clinical consequences.
Registration for the event is available via Fulcrum's website "Events and Presentations" section, with a replay to follow.